Drug Profile


Alternative Names: Benflumetol; CGP 56697; Co-artemether; Coartem; Coartem Dispersible; Exafal; Lumefantrine/artemether; Riamet

Latest Information Update: 01 Apr 2016

Price : $50

At a glance

  • Originator Academy of Military Medical Sciences (Beijing)
  • Developer Medicines for Malaria Venture; Novartis
  • Class Anthelmintics; Antifungals; Antimalarials; Antiprotozoals; Artemisinins; Ethanolamines; Fluorenes; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Carrier protein inhibitors; Hemozoin inhibitors; Mitochondrial protein inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 26 Feb 2016 Preregistration for Malaria in Japan (PO)
  • 08 Apr 2009 Registered for Malaria in USA (PO)
  • 16 Feb 2009 Launched for Malaria in Africa (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top